Molecular epidemiology and outcomes of EGFR exon 20 insertion in Korean patients with non-small cell lung cancer
E20ins represents a small but significant subset of <i>EGFR</i> mutations in aNSCLC, with worse survival outcomes. The study also highlighted superior sensitivity of NGS over PCR in detecting E20ins. This underscores necessity for improved detection strategies and effective treatments tailored to this mutation subgroup.
Authors
- Xiahong Zhao
- Subin Lim (ORCID: https://orcid.org/0000-0001-5379-0796)
- J. Kim
- Dony Patel (ORCID: https://orcid.org/0000-0002-9153-4176)
- Dae Young Yu (ORCID: https://orcid.org/0000-0003-1091-5792)
- Hyehyun Jeong
- Sun Min Lim
- Hyun Suk Jung
- Kyu-Pyo Kim
- Dongkyu Kim
- Seong-Eun Kim
- Dae Ho Lee
- Ji Hyun Kim
- Shinkyo Yoon
- Joohyun Kim
Institutions
- Inje University (KR)
- Ulsan College (KR)
- Yonsei University (KR)
- Asan Medical Center (KR)
- Samsung Medical Center (KR)
- IQVIA (United Kingdom) (GB)
- University of Ulsan (KR)
- IQ Solutions (US)
- Yonsei University Health System (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2026-02-01
- DOI
- https://doi.org/10.21037/tlcr-2025-1-1372
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Yuhan
- Asan Institute for Life Sciences, Asan Medical Center
- Ono Pharmaceutical